T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many.

Abstract

In this issue, Tsimberidou and colleagues report the results of a first-in-human clinical trial using a personalized, multi-target, endogenous T-cell therapy in patients with metastatic solid tumors. This, and results of other recently published clinical trials, confirms the rationale of multi-target approaches that can increase tumor responses and counteract tumor heterogeneity and mechanisms of immune evasion. See related article by Tsimberidou et al., p. 925 (4).